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Abstract
Background: Remifentanil and dexmedetomidine are well known to suppress airway reflexes during airway
procedures. Smooth tracheal extubation is important after otologic surgery. The purpose of this study is to compare
the effectiveness of dexmedetomidine or remifentanil infusion for producing smooth tracheal extubation in deeply
anesthetized patients after otologic surgery.
Methods: Seventy-four ASA I-II adult patients (18-60 years old) scheduled for elective otologic surgery were randomly
assigned to one of three groups: sevoflurane-remifentanil (Group SR, n = 25), sevoflurane-dexmedetomidine (0.5 μg/kg)
(Group SD5, n = 24), or sevoflurane-dexmedetomidine (0.7 μg/kg) (Group SD7, n = 25). Remifentanil or dexmedetomidine
were administered for 10 min at the end of surgery. The primary outcome was the rate of smooth extubation.
Respiratory pattern, airway obstruction, hemodynamic and respiratory profiles, time to awake, rescue analgesics in the
post-anesthesia care unit (PACU), and postoperative nausea and vomiting (PONV) were also recorded.
Results: The rate of smooth tracheal extubation as defined 1 min post-extubation was the same for Groups SR and SD7
(P > 0.05), but the rate of smooth extubation was lower for Group SD5 than for the other two groups (p < 0.05). During
extubation, the respiratory rate was lower in Group SR than in both dexmedetomidine groups (p < 0.05). The
hemodynamic profiles at extubation were similar between groups (p > 0.05), but the mean arterial pressure and heart
rate were higher in Group SR at 10 and 15 min after extubation (p < 0.05). The incidence of airway obstruction and
time to awake were comparable for all groups (p > 0.05). The need for rescue analgesic in the PACU was more
common in Group SR than in both dexmedetomidine groups (P < 0.01). Compared to Group SR, both
dexmedetomidine groups had less PONV on postoperative day 1 (p < 0.05).
Conclusion: Combined with 1 MAC sevoflurane, dexmedetomidine 0.7 ug/kg and remifentanil provided similar
rates for smooth tracheal extubation in spontaneously breathing, anesthetized adults. Dexmedetomidine exhibited
opioid-sparing effects postoperatively and was associated with less PONV than remifentanil.
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Background
Deep extubation refers to the removal of a tracheal tube
in a spontaneously breathing patient who is sufficiently
anesthetized to obtund the laryngeal reflexes [1]. This
technique offers the advantage of a smooth extubation
with less airway stimulation, thereby reducing coughing,
cardiovascular stimulation, and intraocular, intracranial,
and middle ear pressure changes. Removal of the tra-
cheal tube while patients remain deeply anesthetized
may be advantageous in various situations [2]. It is par-
ticularly appealing for otologic surgery, as coughing can
generate acute increases in pressure transmitted to the
middle ear through the eustachian tubes, which may dis-
lodge tympanic membrane grafts or disrupt other re-
pairs. However, the risks of deep tracheal extubation
include increased incidence of airway obstruction and
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Several strategies have been described to conduct a
smooth extubation, including the use of a low dose
remifentanil infusion [3–5]. In our previous study, we
showed that the technique provided smooth extuba-
tion [5]. Remifentanil reduced the sevoflurane require-
ments by 30 % to maintain the same mean arterial
pressure (MAP). However, the main disadvantages of
remifentanil are its ultrashort duration of analgesia
and risk of respiratory depression.
Because of its anxiolytic and analgesic qualities and
lack of respiratory depressant effects, dexmedetomidine
could be an attractive alternative. Although their clinical
pharmacology and mechanisms of action differ, remifen-
tanil and dexmedetomidine share similar properties, in-
cluding suppression of airway reflexes [6–8] and
reduction of sevoflurane requirements [9]. A single dose
of dexmedetomidine (0.5 ug/kg) given before the end of
the surgery was previously reported to attenuate airway
and circulatory reflexes during extubation, without
delaying recovery [10]. Consequently, we hypothesized
that a single dose of dexmedetomidine would function
like low dose remifentanil to facilitate a smooth extuba-
tion when used in combination with 1 MAC sevoflurane.
We therefore conducted this prospective, randomized
trial to compare the effects of remifentanil and dexme-
detomidine when used during deep tracheal extubation
in terms of the rate of smooth extubation, respiratory
and hemodynamic profiles, recovery time, use of rescue
analgesics in the post-anesthesia care unit (PACU), and
incidence of postoperative nausea and vomiting (PONV)
on the first postoperative day.
Methods
After obtaining approval from the Hospital Ethics Com-
mittee (Shanghai Eye, Ear, Nose, and Throat Hospital af-
filiated with Fudan University) and written informed
consent from each patient, we enrolled 75 adult patients
who were 20-60 years of age and undergoing elective
middle ear surgery between March 2013 and September
2013 (trial registry identifier, ChiCTR-TRC-13005025).
All patients were American Society of Anesthesiologists
(ASA) physical status I and II. Patients with chronic lung
disease (e,g., emphysema or bronchitis), a current upper
respiratory infection, asthma, mental disease, a smoking
history, or other congenital diseases were excluded.
Patients with hypertension, a known or suspected diffi-
cult airway (defined as a situation in which a trained
anesthesiologist has difficulty performing facemask
ventilation or tracheal intubation), a history of motion
sickness, and an allergy to parecoxib were also ex-
cluded from the study.
All patients were kept nil per os for a minimum of
8 h before induction of anesthesia. They received no
premedication. Standard ASA monitors were applied,
and the end-tidal sevoflurane concentration was
monitored after intubation. After inserting a 20-
gauge catheter in an arm vein, anesthesia was in-
duced with intravenous (IV) fentanyl 3 μg/kg and
propofol 2.5 mg/kg, and mivacurium 0.2 mg/kg were
administered to facilitate endotracheal intubation.
Prior to the start of surgery, IV boluses of parecoxib
1.0 mg/kg, ondansetron hydrochloride 0.15 mg/kg,
and dexamethasone 0.1 mg/kg were injected, and pa-
tients were randomly assigned to one of three groups
according to a computer-generated random table
until at least 25 patients were assigned to each
group. For anesthesia maintenance, sevoflurane was
adjusted to a MAC of 1.3, and patients received con-
trolled ventilation with an inspired oxygen concentra-
tion of 0.35. At 30 min before the end of surgery, the
patients were allowed to breathe spontaneously after re-
versal agents (neostigmine 0.07 mg/kg and atropine
0.02 mg/kg) were administered to prevent possible re-
sidual block and after return of neuromuscular function
was confirmed using train-of-four peripheral nerve stimu-
lation. Adequate spontaneous respiration was defined as a
normal end-tidal carbon dioxide (ETCO2) waveform and
an ETCO2 concentration less than 6.0 kPa.
At the end of surgery, sevoflurane was reduced to 1.0
MAC and the following infusions were administered for
10 min: remifentanil 0.03 μg/kg/min in Group SR, dex-
medetomidine 0.5 μg/kg in Group SD5, and dexmedeto-
midine 0.7 μg/kg in Group SD7. During the infusion,
patients breathed spontaneously and respiration was not
assisted. Once the infusion was finished, the surgical as-
sistant was allowed to apply the head dressing. The
MAP and heart rate (HR) were maintained within 30 %
of the preanesthetic baseline values in all groups
throughout surgery. Any patient who could not maintain
stable spontaneous respiration while deeply anesthetized
was excluded.
An anesthesiologist, blinded to the assignment and
with 12 years of clinical experience, performed the tra-
cheal extubation using a standardized technique. After
deflating the tracheal tube cuff, the oropharynx was suc-
tioned before gently removing the tube. Sevoflurane was
discontinued immediately after extubation. A nasopha-
ryngeal tube was inserted and oxygen 8 L/min was ad-
ministered via a facemask. The patient was maintained
in the supine position. Smooth tracheal extubation was
defined as no gross purposeful muscular movement,
such as coughing, within 1 min of tracheal tube re-
moval [11]. Patients with coughing, breath holding, or
laryngospasm immediately after extubation were
regarded as not having a smooth tracheal extubation.
The extent of coughing was assessed using a 5-point
scale: 1, no coughing; 2, minimal coughing (1 or 2
times); 3, moderate coughing (3 or 4 times); 4, severe
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coughing (5-10 times) and straining; and 5, and cough-
ing > 10 times [12]. With the patient in supine position,
the upper airway was assessed. Patients were catego-
rized as having a patent or obstructed airway. A patent
airway was defined as an SpO2 > 97 % while receiving
100 % oxygen and the presence of clear breath sounds,
normal chest wall movement, and a normal ETCO2 wave-
form (obtained with a sampling cannula located in the
facemask). Chin-lift was performed by the anesthesiologist
if airway obstruction occurred. An investigator blinded to
the treatment assessed the smoothness of extubation, re-
spiratory pattern, and presence of respiratory complica-
tions. A regular respiratory pattern was defined as a stable
respiratory rate (measured by ETCO2 monitoring) and a
normal ETCO2 waveform. Respiratory and hemodynamic
profiles were recorded before anesthesia, start of infusion,
at extubation, and at 1, 5, 10, and 15 min after extubation.
In the PACU, the time from extubation to awake
(i.e., eye opening on verbal command) was recorded.
Patients remained in the PACU until they achieved a
modified Aldrete score of 9 or 10 [13]. A visual
analogue scale (VAS) score from 0 to 10 (0 = no pain,
10 = worst pain imaginable) was used to assess the
level of pain. If the VAS pain score was > 4, a rescue
analgesic (IV morphine 0.15 mg/kg) was given. All
patients were interviewed by an anesthesia research
nurse on the first postoperative day (during their hos-
pital stay or at home via telephone) regarding their
level of pain and the presence of PONV.
In our previous study, we found that the incidence of
smooth extubation was 90 % in adult patients receiving
sevoflurane and remifentanil combination [14]. Based on
an estimate of a 25 % reduction in the incidence of smooth
extubation, we estimated that a sample of at least 22 pa-
tients per group would be required to detect a significant
difference among groups at an alpha level of 0.05, with a
power of 0.8. Twenty-five patients per group were enrolled
to provide a potential loss of 10 % protocol violation. Con-
tinuous data were reported as mean ± SD. One-way analysis
of variance and post hoc Bonferroni tests were used to com-
pare differences among groups. Nominal data were ana-
lyzed using either x2 or Fisher’s exact tests. Interactions
between time and group factors in a two-way ANOVA with
repeated measurements were used to analyze differences in
hemodynamic profiles (i.e., HR and MAP) between patients
in the three groups. Post hoc Bonferroni tests were used to
compare differences in hemodynamic variables among
groups at specific times. P-values < 0.05 were considered
statistically significant. The primary outcome measurement
was the effect of dexmedetomidine and remifentanil on the
rate of smooth extubation after otologic surgery. The sec-
ondary outcome measures were the respiratory and
hemodynamic profiles during extubation, recovery time,
VAS pain score, and incidence of PONV.
Results
A total of 76 patients were assessed, but surgery was
cancelled for one patient. Thus, 75 patients were enrolled
in the study. One patient in Group SD5 developed respira-
tory depression during the dexmedetomidine infusion and
was excluded from the analysis. A total of 74 patients pro-
gressed through the study: Group SR (n = 25), Group SD5
(n = 24), and Group SD7 (n = 25) (Fig. 1). The demograph-
ics and other characteristics of the three groups are pre-
sented in Table 1. There were no significant differences
between groups for age, weight, sex, duration of
anesthesia, or dose of fentanyl.
In Group SR, 22 patients had a smooth extubation
(no coughing on extubation), 1 patient had minimal
coughing during extubation, and 2 patients had mod-
erate coughing on extubation (Table 2). In Group
SD5, 15 patients had smooth extubation, 6 patients
had episodes of coughing (2 had minimal coughing, 4
had moderate coughing, and 2 had severe coughing,
respectively), and 1 experienced partial laryngospasm,
with a transient reduction in SpO2 to 81 %, which
was treated with continuous positive airway pressure
(CPAP). In Group SD7, 22 patients had smooth tra-
cheal extubation and 3 patients had minimal cough-
ing. The rate of smooth extubation was the same for
Group SR and SD7 (p > 0.05). However, the rate of
smooth extubation was significantly lower in Group
SD5 (p < 0.05). No patient in Group SR or Group
SD7 experienced desaturation, and the only patient
who developed desaturation in Group SD5 was the
individual who developed laryngospasm. No patient
required re-intubation. The occurrence of airway ob-
struction was comparable in the three groups (p > 0.05).
There was a tendency for more patients in Group SR
and Group SD7 to maintain a regular respiratory pat-
tern during dressing application, although the difference
between groups did not reach statistical significance
(p > 0.05). The percentage of patients with a regular re-
spiratory pattern during cuff deflation was lower in
Group SD5 (0.75, 95 % CI: 0.53-0.90) than in Group
SD7 (0.88, 95 % CI: 0.69-0.97) and Group SR (1.00,
95 % CI: 0.86-1.00), P < 0.05.
At the time of extubation, the respiratory rate was signifi-
cantly lower in Group SR (6.9 breaths/min) than in either
dexmedetomidine group (Group SD5, 12.3 breaths/min;
Group SD7, 12.2 breaths/min; P < 0.05) (Table 3). However,
the respiratory rate in Group SR rose to a mean of 10
breaths/min at 5 min after discontinuing remifentanil. Tidal
volume was higher in Group SR than in both dexmedeto-
midine groups (Group SR, 397.2 ± 136.9 ml; Group SD5,
275.7 ± 76.4 ml; Group SD7, 266.2 ± 70.3 ml; P < 0.05).
ETCO2 was comparable among groups (P > 0.05).
MAP was comparable between groups before anesthesia,
start of infusion, at extubation, and at 1 and 5 min after
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extubation (Fig. 2). However, MAP was significantly higher
at 10 and 15 min after extubation in Group SR than in the
dexmedetomidine groups (P < 0.05). HR was higher in
Group SR than in the dexmedetomidine groups at 5, 10,
and 15 min after extubation (P < 0.05) (Fig. 2).
In the PACU, no patient developed oxygen desatur-
ation. One 18-year-old male in Group SR exhibited agi-
tation, which was treated with propofol and morphine.
The time from extubation to awake (eye opening on
verbal command) was comparable in the three groups
Table 1 Demographics and clinical characteristics
Variable Group SR Group SD5 Group SD7 P value
(n = 25) (n = 24) (n = 25)
Sex (male/female) 15/10 13/12 14/11 0.32
Age (y) 42.3 ± 13.2 44.3 ± 14.3 40.0 ± 11.7 0.52
Weight (kg) 63.2 ± 10.0 61.4 ± 11.1 62.9 ± 11.0 0.82
Anesthesia duration
(min)
109.0 ± 45.6 101.6 ± 31.0 109.5 ± 43.3 0.75
Dose of fentanyl (μg) 211.7 ± 40.3 216.5 ± 40.4 217.2 ± 42.0 0.84
Data are expressed as mean ± standard deviation (One-way ANOVA test) or
number of patients (Chi Square test)
SR sevoflurane-remifentanil group, SD5 sevoflurane-dexmedetomidine group
(0.5 μg/kg), SD7 sevoflurane-dexmedetomidine group (0.7 μg /kg)
Fig. 1 CONSORT flow diagram
Table 2 Extubation characteristics, respiratory complications,
and respiratory pattern
Study group Group SR Group SD5 Group SD7 P value
(n = 25) (n = 24) (n = 25)
Smooth extubation 22 (88.0) 15 (62.5) 22 (88.0) 0.038
Coughing extent 0.096
No coughing 22 15 22
Minimal coughing 1 (4.0) 2 (8.3) 3 (12.0)
Moderate coughing 2 (8.0) 4 (16.7) 0
Severe coughing 0 2 (8.3) 0
Respiratory complications
Laryngospasm 0 1 (4.2) 0 0.35
Desaturation (SpO2 < 90 %) 0 1 (4.2) 0 0.35




20 (80.0) 15 (62.5) 19 (76.0) 0.35
During cuff deflation 25 (100) 18 (75.0) 22 (88.0) 0.028
Data are expressed as number of patients (%) (Chi-Square test)
SR sevoflurane-remifentanil group, SD5 sevoflurane-dexmedetomidine group
(0.5 μg/kg), SD7 sevoflurane-dexmedetomidine group (0.7 μg /kg)
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(p > 0.05). However, more patients in Group SR re-
quired morphine for analgesia rescue (p < 0.001). The
incidence of PONV (1 or 2 on the PONV scale) was
lower in Group SD5 and Group SD7 than in Group
SR (p < 0.05) (Table 4).
Discussion
The main result of our study was that during sevoflurane-
based anesthesia, dexmedetomidine infusion 0.7 μg/kg ad-
ministered over 10 min at the end of surgery produced a
dose-dependent effect in providing smooth extubation
without significantly prolonging recovery from anesthesia.
Compared to remifentanil, the benefits of dexmedetomi-
dine included hemodynamic stability, opioid sparing, and
less PONV. The disadvantages of dexmedetomidine in-
cluded lower tidal volume and blood pressure.
If endotracheal intubation is utilized, smooth emer-
gence from anesthesia may be a challenge in many pa-
tients undergoing otologic surgery. Laryngeal responses,
with bucking and coughing on emergence from
anesthesia, are undesirable, since the pressure transmit-
ted through the eustachian tubes may unseat a tym-
panic membrane graft or disrupt other repairs [15].
Accordingly, many anesthesiologists prefer to perform
tracheal extubation when the spontaneously breathing
patient remains at a deep plane of anesthesia [1]. A key
aspect of the deep extubation technique is for airway
reflexes to be effectively suppressed at the time of extu-
bation, but resume as soon as possible after extubation.
Because of remifentanil’s analgesic and antitussive prop-
erties, the combination of sevoflurane and remifentanil
[5, 16] is commonly used to decrease the MAC of
sevoflurane and facilitate a more rapid recovery.
Dexmedetomidine, like remifentanil, has been shown
to decrease sevoflurane MAC [7, 17]. Several studies
have confirmed the efficacy of both remifentanil and
dexmedetomidine for airway reflex suppression during
flexible bronchoscopy and awake intubation [7, 8]. In
addition, Guler et al. [10] reported that a single dose of
dexmedetomidine (0.5 μg/kg) before the end of the sur-
gery attenuated airway reflexes during extubation. In the
current study, when combined with 1 MAC sevoflurane,
both dexmedetomidine 0.7 μg/kg and remifentanil effect-
ively suppressed airway reflexes and facilitated smooth
extubation in deeply anesthetized patients. Compared to
Group SD5, the higher dose of dexmedetomidine in Group
Table 3 Respiratory profiles at extubation
Study group Group SR Group SD5 Group SD7 P value
(n = 25) (n = 24) (n = 25)
Respiratory rate
(breaths /min)
6.9 ± 1.8 12.3 ± 5.2 ^^ 12.2 ± 3.5** <0.0001
Tidal volume
(ml)
397.2 ± 136.9 275.7 ± 76.4^^ 266.2 ± 70.3** <0.0001
ETCO2 (mm Hg) 55.6 ± 10.3 52.3 ± 9.3 51.4 ± 8.6 0.26
Data are expressed as mean ± standard deviation
SR sevoflurane-remifentanil group, SD5 sevoflurane-dexmedetomidine group
(0.5 μg/kg), SD7 sevoflurane-dexmedetomidine group (0.7 μg /kg)
**P < 0.001 (One-way ANOVA test), Group SD7 compared to Group SR
^^P < 0.001 (One-way ANOVA test), Group SD5 compared to Group SR
Fig. 2 Hemodynamic changes in the three groups. T0 (before
anesthesia); Tin, start of infusion; T1, at the time extubation; T1,
1 min after extubation; T2, 5 min after extubation; T3, 10 min after
extubation; T4; 15 min after extubation. ^p < 0.05, Group SD5
compared to Group SR; *p < 0.05, Group SD7 compared to Group SR.
Changes in MAP (a) and HR (b) in three groups at different
perioperative time points
Table 4 Recovery variables in the post-anesthesia care unit and
on postoperative Day 1
Study group Group SR Group SD5 SD7 P value
(n = 25) (n = 24) (n = 25)
Time to awake (min) 17.6 ± 5.4 19.6 ± 5.7 20.2 ± 5.7 0.24
Rescue analgesia (patients) 18 (72.0) 5 (20.8) 4 (16.0 0.0005
Incidence of PONV 12 (48.0) 4 (16.7) 4 (16.0) 0.015
Data are expressed as mean ± standard deviation (One-way ANOVA test) or
number of patients (percentage) (Chi-Square test)
SR sevoflurane-remifentanil group, SD5 sevoflurane-dexmedetomidine group
(0.5 μg/kg), SD7 sevoflurane-dexmedetomidine group (0.7 μg/kg), PONV
postoperative nausea and vomiting
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SD7 was associated with a higher percentage of patients
with a smooth extubation. In addition, compared to
Group SR and Group SD5, patients receiving dexme-
detomidine 0.7 μg/kg did not exhibit a prolonged
time to wake.
If general endotracheal anesthesia is used during oto-
logic surgery, a deep stage of anesthesia is required until
the end of procedure to avoid bucking and coughing as-
sociated with head movement during application of the
surgical dressing. In the current study, the majority of
patients in all groups maintained a regular respiratory
pattern during dressing application and tracheal tube
cuff deflation, and when patients maintained a regular
respiratory pattern during dressing application, tracheal
extubation could be performed smoothly in all cases. It
is generally accepted that the absence of a reaction and
maintenance of regular respirations during tracheal tube
cuff deflation is a reliable predictor of a smooth deep
extubation [18]. In our experience, airway stimulation is
greater during dressing application than during cuff de-
flation. Thus, a regular respiratory pattern during dress-
ing application is a more reliable predictor of smooth
tracheal extubation in spontaneously breathing anesthe-
tized patients after otologic surgery.
In the current study, the respiratory rate during tra-
cheal extubation was lower in Group SR than in Group
SD5 or Group SD7. This result was consistent with the
known respiratory depressant effects of remifentanil,
which does not occur with dexmedetomidine. However,
there was an exception, as one spontaneously breathing
patient in Group SD5 exhibited apnea during dexmede-
tomidine infusion. The underlying reason for this was
unclear. Moreover, the mean tidal volume was lower in
patients receiving dexmedetomidine. We speculated
that in presence of sevoflurane, the respiratory de-
pression caused by sevoflurane and dexmedetomidine
may reflect decrease in central respiratory drive medi-
ated by both GABAA and alpha-2 adrenergic recep-
tors. The potential disadvantages of dexmedetomidine
are hemodynamic changes, such as decrease in heart
rate and/or increased or decreased blood pressure,
but those adverse effects can be prevented by admin-
istering dexmedetomidine over 10 min. In our study,
hemodynamic effects were clinically insignificant in
patients receiving dexmeedetomidine.
Another disadvantage of remifentanil is its ultrashort
duration of analgesia. Our findings were consistent with
this disadvantage. For example, the increase in MAP and
HR after extubation reflected rapid dissipation of the ef-
fects of remifentanil. Furthermore, morphine for rescue
analgesia in the PACU was required by 18 patients in
Group SR, but only by 5 and 4 patients in Groups SD5
and SD7, respectively. In addition, one 18-year-old
patient in Group SR experienced agitation. When he
regained full consciousness, he reported bad dreams and
requested analgesia.
Arsian et al. [19] reported that the incidence of PONV
for patients undergoing otologic surgery was as high as
65.7 %, which could be reduced to 22.9 % by the use of
prophylactic antiemetic drugs. Apfel et al. [20] recom-
mended first-line strategy with dexamethasone and a 5-
HT receptor antagonist to prevent PONV. In our
current study, we found that fewer patients in Group
SD5 and Group SD7 reported PONV on the first post-
operative day, compared to patients in Group SR. This
may be attributable to the opioid-sparing and antiemetic
properties of dexmedetomidine.
The potential risks of extubation at a deep level of
anesthesia include aspiration, airway obstruction, desat-
uration, and loss of airway control. In our study, we did
not observe aspiration, severe laryngospasm, or desatur-
ation in any of the three groups from the time of tra-
cheal extubation to full recovery. Several factors likely
contributed to these findings. First, the patients in our
study were well fasted. Second, we used relatively short-
acting anesthetic agents and adjuncts, including fen-
tanyl, sevoflurane, and remifentanil. We also used the
short-acting muscle relaxant mivacurium and objectively
confirmed the return of neuromuscular function. Third,
patients who experienced a smooth extubation main-
tained a regular respiratory pattern during dressing ap-
plication, a maneuver that produced major stimulation
of the airway. Fourth, the oropharynx was well suc-
tioned before extubation.
There are several limitations in our study. First,
during extubation at a deep level of anesthesia, we
placed the patient in a supine instead of lateral pos-
ition. Our rationale for this position was that if loss
of the airway occurred, the anesthesiologist could
more quickly manage the airway when patients were
supine. Second, we monitored anesthesia depth by
clinical signs rather than the bispectral index (BIS).
We acknowledge that BIS may have provided useful
information, but BIS monitoring was not routinely
available at our hospital and we wanted our study to
reflect usual clinical conditions. Third, this study in-
volved highly selected, healthy patients undergoing
middle ear surgery, who had no history or physical
characteristics suggesting potential airway difficulties.
Thus, it is uncertain whether our results can be gen-
eralized to other populations. Fourth, Insommo [11]
suggested that tracheal extubation could be performed
at nearly 1 MAC sevoflurane. However, we have
found that with the anesthesia technique described in
the Materials section of that study, we are unable to
achieve a smooth extubation for patients after oto-
logic surgery. Instead, we routinely perform tracheal
extubation at either 1.3 MAC sevoflurane anesthesia
Fan et al. BMC Anesthesiology  (2015) 15:106 Page 6 of 7
or at 1 MAC sevoflurane in combination with low-
dose remifentanil, as was used in this study [5]. Fifth,
evaluation of smooth extubation was limited in the
first 1 min after deep extubation. 1 min is a narrow
interval. Though respiratory complication usually hap-
pens immediately after extubation, patients should be
closely monitored during emergence.
Conclusion
In summary, our study showed that similar to remifenta-
nil, dexmedetomidine 0.7 μg/kg produced smooth tra-
cheal extubation in adult patients deeply anesthetized
with sevoflurane after otologic surgery. In addition, dex-
medetomidine exhibited opioid-sparing effects and pro-
duced less PONV than remifentanil.
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